Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in